Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
2.

Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.

Cohen S, Waks Z, Elm JJ, Gordon MF, Grachev ID, Navon-Perry L, Fine S, Grossman I, Papapetropoulos S, Savola JM.

BMC Med Inform Decis Mak. 2018 Dec 20;18(1):138. doi: 10.1186/s12911-018-0714-7.

3.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
4.

Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.

Schneider F, Erisson L, Beygi H, Bradbury M, Cohen-Barak O, Grachev ID, Guzy S, Loupe PS, Levi M, McDonald M, Savola JM, Papapetropoulos S, Tracewell WG, Velinova M, Spiegelstein O.

Br J Clin Pharmacol. 2018 Oct;84(10):2422-2432. doi: 10.1111/bcp.13702. Epub 2018 Aug 9.

5.

Successful Surgical Treatment of an Aggressive Pelvic Angiomyxoma With Intracardiac Extension.

Husso A, Savola J, Gunn J.

Ann Thorac Surg. 2017 Jul;104(1):e23-e25. doi: 10.1016/j.athoracsur.2017.01.118.

PMID:
28633254
6.

Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).

Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P.

J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309.

7.

A 6-Year Single-Center Experience of Intra-aortic Balloon Pump Treatment--Retrospective Analysis of 223 Patients.

Saura E, Savola J, Gunn J.

J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1410-4. doi: 10.1053/j.jvca.2015.04.014. Epub 2015 Apr 16.

PMID:
26159743
8.

[Thoracoscopic ablation of atrial fibrillation].

Koistinen J, Alin M, Vilkki V, Savola J.

Duodecim. 2013;129(1):57-63. Review. Finnish.

PMID:
23431883
9.

Microwave Ablation in Mitral Valve Surgery for Atrial Fibrillation (MAMA).

Jönsson A, Lehto M, Ahn H, Hermansson U, Linde P, Ahlsson A, Koistinen J, Savola J, Raatikainen P, Lepojärvi M, Sahlman A, Werkkala K, Toivonen L, Walfridsson H.

J Atr Fibrillation. 2012 Aug 20;5(2):432. doi: 10.4022/jafib.432. eCollection 2012 Aug-Sep.

10.

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).

Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM.

Neurology. 2012 Jul 10;79(2):163-9. doi: 10.1212/WNL.0b013e31825f0451. Epub 2012 Jun 27.

PMID:
22744665
11.

Left-sided diaphragmatic and pericardial ruptures with subluxation of the heart after blunt trauma.

Gunn JM, Savola J, Isotalo K.

Ann Thorac Surg. 2012 Jan;93(1):317-9. doi: 10.1016/j.athoracsur.2011.05.046.

PMID:
22186460
12.

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM.

Mov Disord. 2010 Oct 15;25(13):2084-93. doi: 10.1002/mds.23172.

PMID:
20824735
13.

Human kisspeptins activate neuropeptide FF2 receptor.

Lyubimov Y, Engstrom M, Wurster S, Savola JM, Korpi ER, Panula P.

Neuroscience. 2010 Sep 29;170(1):117-22. doi: 10.1016/j.neuroscience.2010.06.058. Epub 2010 Jul 1.

PMID:
20600636
14.

Minimally invasive repair for treating pectus excavatum--early results.

Hurme T, Savola J, Vilkki V.

Scand J Surg. 2008;97(1):63-70.

PMID:
18450208
15.

Thoracoscopic microwave ablation of atrial fibrillation.

Koistinen J, Valtonen M, Savola J, Airaksinen J.

Interact Cardiovasc Thorac Surg. 2007 Dec;6(6):695-8. Epub 2007 Aug 15.

PMID:
17699543
16.

Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.

Sallinen J, Höglund I, Engström M, Lehtimäki J, Virtanen R, Sirviö J, Wurster S, Savola JM, Haapalinna A.

Br J Pharmacol. 2007 Feb;150(4):391-402. Epub 2007 Jan 15.

17.

Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists.

Höglund IP, Silver S, Engström MT, Salo H, Tauber A, Kyyrönen HK, Saarenketo P, Hoffrén AM, Kokko K, Pohjanoksa K, Sallinen J, Savola JM, Wurster S, Kallatsa OA.

J Med Chem. 2006 Oct 19;49(21):6351-63.

PMID:
17034141
18.
19.

Assessing activation of the human neuropeptide FF2 receptor with a non-radioactive GTP binding assay.

Engström M, Närvänen A, Savola JM, Wurster S.

Peptides. 2004 Dec;25(12):2099-104.

PMID:
15572197
20.

Superagonism at the human somatostatin receptor subtype 4.

Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S.

J Pharmacol Exp Ther. 2005 Jan;312(1):332-8. Epub 2004 Aug 27.

PMID:
15333679
21.

Functional properties of Pfr(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors.

Engström M, Wurster S, Savola JM, Panula P.

Peptides. 2003 Dec;24(12):1947-54.

PMID:
15127947
22.

Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Peltonen JM, Nyrönen T, Wurster S, Pihlavisto M, Hoffrén AM, Marjamäki A, Xhaard H, Kanerva L, Savola JM, Johnson MS, Scheinin M.

Br J Pharmacol. 2003 Sep;140(2):347-58. Epub 2003 Aug 18.

23.
24.

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.

Mov Disord. 2003 Aug;18(8):872-83.

PMID:
12889076
25.

Prolactin releasing peptide has high affinity and efficacy at neuropeptide FF2 receptors.

Engström M, Brandt A, Wurster S, Savola JM, Panula P.

J Pharmacol Exp Ther. 2003 Jun;305(3):825-32. Epub 2003 Feb 20.

PMID:
12606605
26.

Interaction of folk medicinal plant extracts with human alpha2-adrenoceptor subtypes.

Saleem A, Engström M, Wurster S, Savola JM, Pihlaja K.

Z Naturforsch C. 2002 Mar-Apr;57(3-4):332-8.

PMID:
12064736
27.

Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine.

Nyrönen T, Pihlavisto M, Peltonen JM, Hoffrén AM, Varis M, Salminen T, Wurster S, Marjamäki A, Kanerva L, Katainen E, Laaksonen L, Savola JM, Scheinin M, Johnson MS.

Mol Pharmacol. 2001 May;59(5):1343-54.

PMID:
11306720
28.

Successful treatment of mediastinal gas gangrene due to esophageal perforation.

Salo JA, Savola JK, Toikkanen VJ, Perhoniemi VJ, Pettilä VY, Klossner JA, Toivonen HJ.

Ann Thorac Surg. 2000 Dec;70(6):2143-5.

PMID:
11156138
30.

[Treatment of claudication].

Savola J.

Duodecim. 1998;114(3):269. Finnish. No abstract available.

PMID:
10895499
31.

Life-threatening Mycoplasma hominis mediastinitis.

Mattila PS, Carlson P, Sivonen A, Savola J, Luosto R, Salo J, Valtonen M.

Clin Infect Dis. 1999 Dec;29(6):1529-37. Review.

PMID:
10585808
32.

Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding.

Salminen T, Varis M, Nyrönen T, Pihlavisto M, Hoffrén AM, Lönnberg T, Marjamäki A, Frang H, Savola JM, Scheinin M, Johnson MS.

J Biol Chem. 1999 Aug 13;274(33):23405-13.

33.

Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner.

Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M.

Eur J Pharmacol. 1999 Jun 11;374(1):137-46.

PMID:
10422650
34.

Protean agonism at alpha2A-adrenoceptors.

Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R, Savola JM, Cockcroft V, Akerman KE.

Mol Pharmacol. 1998 May;53(5):963-8.

PMID:
9584224
35.

A series of 6-(omega-methanesulfonylthioalkoxy)-2-N-methyl- 1,2,3, 4-tetrahydroisoquinolines: cysteine-reactive molecular yardsticks for probing alpha2-adrenergic receptors.

Heinonen P, Koskua K, Pihlavisto M, Marjamäki A, Cockcroft V, Savola JM, Scheinin M, Lönnberg H.

Bioconjug Chem. 1998 May-Jun;9(3):358-64.

PMID:
9576810
36.

Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor.

Marjamaki A, Pihlavisto M, Cockcroft V, Heinonen P, Savola JM, Scheinin M.

Mol Pharmacol. 1998 Mar;53(3):370-6.

PMID:
9495800
37.

Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine.

Haapalinna A, Viitamaa T, MacDonald E, Savola JM, Tuomisto L, Virtanen R, Heinonen E.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):570-82.

PMID:
9402036
38.

Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2-adrenoceptor antagonists.

Kukkonen JP, Huifang G, Jansson CC, Wurster S, Cockcroft V, Savola JM, Akerman KE.

Eur J Pharmacol. 1997 Sep 17;335(1):99-105.

PMID:
9371550
39.

Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase.

Pohjanoksa K, Jansson CC, Luomala K, Marjamäki A, Savola JM, Scheinin M.

Eur J Pharmacol. 1997 Sep 17;335(1):53-63.

PMID:
9371546
40.

Anti-obesity effect of MPV-1743 A III, a novel imidazoline derivative, in genetic obesity.

Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R.

Eur J Pharmacol. 1997 Jun 11;328(2-3):207-15.

PMID:
9218703
41.

alpha 2A/D-Adrenoceptor subtype predominates also in the neonatal rat spinal cord.

Savola MK, Savola JM.

Brain Res Dev Brain Res. 1996 Jun 14;94(1):106-8.

PMID:
8816283
42.
43.

Value of high-resolution computed tomography in routine evaluation of lung transplantation recipients during development of bronchiolitis obliterans syndrome.

Ikonen T, Kivisaari L, Harjula AL, Lehtola A, Heikkilä L, Kinnula VL, Kyösola K, Savola J, Sipponen J, Verkkala K, Mattila SP.

J Heart Lung Transplant. 1996 Jun;15(6):587-95.

PMID:
8803756
44.

Selective assessment of single-lung graft function with 133Xe radiospirometry in acute rejection and infection.

Ikonen T, Harjula AL, Kinnula V, Savola J, Sovijärvi AR.

Chest. 1996 Apr;109(4):879-84.

PMID:
8635364
45.

Alpha 2A-adrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes.

Vikman HL, Savola JM, Raasmaja A, Ohisalo JJ.

Int J Obes Relat Metab Disord. 1996 Feb;20(2):185-9.

PMID:
8646256
46.

[Meningitis caused by Francisella Tularensis].

Hakola K, Savola J.

Duodecim. 1996;112(14):1300-2. Finnish. No abstract available.

PMID:
10596102
47.

Assessment of FEV1 fraction of the transplant and the native lung with 133Xe radiospirometry after single lung transplantation.

Ikonen T, Harjula A, Savola J, Mattila S, Sovijärvi A.

Transplant Proc. 1995 Dec;27(6):3488. No abstract available.

PMID:
8540062
48.
49.

Nonadrenergic binding of [3H]atipamezole in rat lung. A novel imidazole binding site?

Sjöholm B, Savola JM, Scheinin M.

Ann N Y Acad Sci. 1995 Jul 12;763:66-77. No abstract available.

PMID:
7677386
50.

Evaluation of the development of bronchiolitis obliterans syndrome in single lung recipients by assessment of transplant FEV1 with 133-XE radiospirometry.

Ikonen T, Harjula AL, Kinnula V, Savola J, Sovijärvi AR.

Transplant Proc. 1995 Jun;27(3):2008. No abstract available.

PMID:
7792869

Supplemental Content

Loading ...
Support Center